A panel convened by the U.S. Food and Drug Administration voted yesterday against approval of the experimental diabetes drug, dapagliflozin, citing safety concerns associated with use of the drug, including increased risk for bladder and breast cancers. The panel concluded that while the drug, which is the first-of-its-kind, had attractive features as a treatment for [...]
